[1] |
Kudryavtseva AV, Neskorodova KA, Staubach P. Urticaria in children and adolescents: an updated review of the pathogenesis and management[J]. Pediatr Allergy Immunol, 2019,30(1):17⁃24. doi: 10.1111/pai.12967.
|
[2] |
Cornillier H, Giraudeau B, Munck S, et al. Chronic spontaneous urticaria in children ⁃ a systematic review on interventions and comorbidities[J]. Pediatr Allergy Immunol, 2018,29(3):303⁃310. doi: 10.1111/pai.12870.
|
[3] |
Sirufo MM, Ginaldi L, De Martinis M. Successful treatment with omalizumab in a child with asthma and urticaria: a clinical case report[J]. Front Pediatr, 2019,7:213. doi: 10.3389/fped. 2019.00213.
|
[4] |
Lee JK, Simpson RS. Dupilumab as a novel therapy for difficult to treat chronic spontaneous urticaria[J]. J Allergy Clin Immunol Pract, 2019,7(5):1659⁃1661.e1. doi: 10.1016/j.jaip.2018.11.018.
|
[5] |
中华医学会皮肤性病学分会荨麻疹研究中心. 中国荨麻疹诊疗指南(2022版)[J]. 中华皮肤科杂志, 2022,55(12):1041⁃1049. doi: 10.35541/cjd.20220609.
|
[6] |
中华医学会皮肤性病学分会免疫学组, 特应性皮炎协作研究中心. 中国特应性皮炎诊疗指南(2020版)[J]. 中华皮肤科杂志, 2020,53(2):81⁃88. doi: 10.35541/cjd.20191000.
|
[7] |
Kolkhir P, Altrichter S, Munoz M, et al. New treatments for chronic urticaria[J]. Ann Allergy Asthma Immunol, 2020,124(1):2⁃12. doi: 10.1016/j.anai.2019.08.014.
|
[8] |
Hendricks AJ, Yosipovitch G, Shi VY. Dupilumab use in dermatologic conditions beyond atopic dermatitis ⁃ a systematic review[J]. J Dermatolog Treat, 2021,32(1):19⁃28. doi: 10.1080/09546634.2019.1689227.
|
[9] |
Sirufo MM, Catalogna A, Raggiunti M, et al. Cholinergic urticaria, an effective and safe "off label" use of dupilumab: a case report with literature review[J]. Clin Cosmet Investig Dermatol, 2022,15:253⁃260. doi: 10.2147/CCID.S343462.
|
[10] |
Föhr J, Herbst M, Jahn S. Treatment of simultaneously occurring urticaria and atopic dermatitis with dupilumab[J]. Hautarzt, 2021,72(3):249⁃251. doi: 10.1007/s00105⁃020⁃04675⁃3.
|
[11] |
Sun Y, Lin SY, Lan CE. Dupilumab as a rescue therapy for a chronic urticaria patient who showed secondary failure to omalizumab[J]. Kaohsiung J Med Sci, 2022,38(6):610⁃611. doi: 10.1002/kjm2.12531.
|
[12] |
Abadeh A, Lee JK. Long⁃term follow⁃up of patients treated with dupilumab for chronic spontaneous urticaria: a case report[J]. SAGE Open Med Case Rep, 2022,10:2050313X221117702. doi: 10.1177/2050313X221117702.
|
[13] |
Goodman B, Jariwala S. Dupilumab as a novel therapy to treat adrenergic urticaria[J]. Ann Allergy Asthma Immunol, 2021,126(2):205⁃206. doi: 10.1016/j.anai.2020.06.034.
|
[14] |
Errichetti E, Stinco G. Recalcitrant chronic urticaria treated with dupilumab: report of two instances refractory to H1⁃antihistamines, omalizumab and cyclosporine and brief literature review[J]. Dermatol Ther, 2021,34(2):e14821. doi: 10.1111/dth.14821.
|
[15] |
Holm JG, Sørensen JA, Thomsen SF. Concurrent use of omalizumab and dupilumab in a 47⁃year⁃old woman with chronic spontaneous urticaria and atopic dermatitis[J]. Int J Dermatol, 2022,61(5):e173⁃e174. doi: 10.1111/ijd.16009.
|
[16] |
Puxkandl V, Hoetzenecker W, Altrichter S. Case report: severe chronic spontaneous urticaria successfully treated with omalizumab and dupilumab[J]. Allergol Select, 2023,7:17⁃19. doi: 10.5414/ALX02382E.
|
[17] |
Ferrucci S, Benzecry V, Berti E, et al. Rapid disappearance of both severe atopic dermatitis and cold urticaria following dupilumab treatment[J]. Clin Exp Dermatol, 2020,45(3):345⁃346. doi: 10.1111/ced.14081.
|
[18] |
Marchal V, Reguiai Z. Efficacity of dupilumab in severe idiopathic cold urticaria: a case report[J]. J Dermatolog Treat, 2023,34(1):2182620. doi: 10.1080/09546634.2023.2182620.
|
[19] |
Zhu C, Fok JS, Lin L, et al. Complete response to dupilumab in a patient with chronic spontaneous urticaria who did not tolerate omalizumab[J]. JAAD Case Rep, 2023,32:109⁃112. doi: 10. 1016/j.jdcr.2022.12.009.
|